29 names are moving together; 69% are participating in the current session.
Observed member paths adjusted against SPY. Shading marks the latest observation window.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| DRUG | Bright Minds Biosciences Inc. | Healthcare | -3.0% | Group member |
| VKTX | Viking Therapeutics, Inc. | Healthcare | -1.8% | Group member |
| IMTX | Immatics N.V. | Healthcare | -4.5% | 1/7 observed active sessions |
| BBIO | BridgeBio Pharma, Inc. | Healthcare | -3.4% | Group member |
| ROIV | Roivant Sciences Ltd. | Healthcare | -4.1% | Group member |
| JANX | Janux Therapeutics, Inc. | Healthcare | -1.7% | 1/7 observed active sessions |
| ANRO | Alto Neuroscience, Inc. | Healthcare | +5.9% | Group member |
| DYN | Dyne Therapeutics, Inc. | Healthcare | +0.8% | Group member |
| IMMX | Immix Biopharma, Inc. | Healthcare | -5.6% | 1/7 observed active sessions |
| STOK | Stoke Therapeutics, Inc. | Healthcare | -6.2% | 1/7 observed active sessions |
| AKBA | Akebia Therapeutics, Inc. | Healthcare | -1.1% | 1/7 observed active sessions |
| AMLX | Amylyx Pharmaceuticals, Inc. | Healthcare | -2.1% | Group member |
| NUVB | Nuvation Bio Inc. | Healthcare | -0.7% | Group member |
| CRBP | Corbus Pharmaceuticals Holdings | Healthcare | -6.5% | Group member |
| RVMD | Revolution Medicines, Inc. | Healthcare | -1.5% | Group member |
| PCVX | Vaxcyte, Inc. | Healthcare | -2.0% | Group member |
| UNCY | Unicycive Therapeutics, Inc. | Healthcare | -2.4% | Group member |
| IDYA | IDEAYA Biosciences, Inc. | Healthcare | -2.1% | 1/7 observed active sessions |
| KOD | Kodiak Sciences Inc | Healthcare | -0.4% | Group member |
| VIR | Vir Biotechnology, Inc. | Healthcare | -2.5% | Group member |
| GERN | Geron Corporation | Healthcare | -5.7% | 1/7 observed active sessions |
| VERA | Vera Therapeutics, Inc. | Healthcare | -1.2% | Group member |
| TECX | Tectonic Therapeutic, Inc. | Healthcare | -0.3% | 1/7 observed active sessions |
| CELC | Celcuity Inc. | Healthcare | -3.4% | Group member |
Cohort
29 namesParticipation
69% this sessionObserved history
11 daily buildsFiling coverage
27/29 membersproduct pipeline / R&D affecting expense
“The decrease was partially offset by a $17.3 million increase in expenses related to the pivotal Phase 3 LUCIDITY clinical trial in PBH and other costs related to avexitide, a $2.0 million increase in expenses related to AMX0035 for the treatment of PSP, and a $2.1 million increase in expenses related to other research and development activities.”
AMLX 10-Q
credit / rates affecting interest expense
“The increase was primarily due to higher non-cash interest expense related to the settlement royalty liability in connection with the Vifor Termination Agreement, which we entered into in July 2024, partially offset by interest income related to our money market funds.”
AKBA 10-K
product pipeline / R&D
“Vadadustat Global Phase 3 Clinical Program in Anemia Due To CKD We conducted a global Phase 3 clinical development program for vadadustat, which included two programs, INNO 2 VATE and PRO 2 TECT.”
AKBA 10-K
This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
PTGXcustomer · Not moving with the group now
Filing receipt · PFE / PTGX
“Pfizer, which completed its acquisition of Metsera in 2025, is developing next-generation oral and peptide-based incretin therapies for obesity and related cardiometabol…”
PTGX · customer
ARWRpartner · Not moving with the group now
Filing receipt · AMGN / ARWR
“Over the past several years we have entered into license and collaboration agreements with Takeda, Janssen, Amgen, Horizon, GSK, Sarepta, Visirna and Novartis Pharma AG…”
ARWR · partner
ARWRpartner · Not moving with the group now
Filing receipt · SNY / ARWR
“Under our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development…”
ARWR · partner
PCVXcustomer · Not moving with the group now
Filing receipt · STRO / PCVX
“Blackstone Relationship In June 2023, we entered into a purchase and sale agreement with Blackstone, or the Blackstone Agreement, to sell to Blackstone a revenue interes…”
PCVX · customer
JANXpartner · Moving with the group now · 115 min observed
Filing receipt · MRK / JANX
“In addition to our wholly-owned pipeline programs, we have strategic research collaborations with Merck Sharp & Dohme Corp.”
JANX · partner